SCHEMBL3391803

SCHEMBL3391803

COCC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.60
MAPT P10636 1/20 0.60
PTPN1 P18031 2/20 0.59
GSK3B P49841 1/20 0.59
CES2 O00748 1/20 0.53
CES1 P23141 1/20 0.53
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.50
MMP8 P22894 1/20 0.50
GRM4 Q14833 1/20 0.49
PDPK1 O15530 1/20 0.49
HSD11B1 P28845 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
SRD5A2 P31213 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
MAOB P27338 1/20 0.46
NR4A1 P22736 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3320943 0.88 ALDH1A1 (0.56) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL5789171 0.83 ALDH1A1 (0.62) ALDH1A1MAPTHDAC1SRD5A2HTT
SCHEMBL22118738 0.81 ALDH1A1 (0.47) ALDH1A1MAPTPTPN1GSK3BHDAC1
SCHEMBL31423428 0.81 PTPN1 (0.59) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL830420 0.80 PTPN1 (0.62) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL2542330 0.80 ALDH1A1 (0.55) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL5369280 0.80 CES2 (0.59) ALDH1A1CES2HDAC1SRD5A2KMT2A
SCHEMBL27743871 0.80 ALDH1A1 (0.55) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL29200055 0.79 PTPN1 (0.56) ALDH1A1MAPTPTPN1GSK3BCES2
SCHEMBL7847608 0.79 PTPN1 (0.60) ALDH1A1MAPTPTPN1GSK3BCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249411-A1 Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines WU WENXUE 2010-09-30 US claimed
EP-2141143-A2 Stereoselective alkylation of chiral 2-methyl-4 protected piperazines SCHERING CORPORATION (US) 2010-01-06 EP claimed
US-20050171120-A1 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines WU WENXUE (US) 2005-08-04 US claimed
CN-1642930-A Stereoselective alkylation of chiral 2-methyl-4-protected piperazines SCHERING CORP (US) 2005-07-20 CN claimed
EP-1490346-A2 STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES SCHERING CORPORATION (US) 2004-12-29 EP claimed
US-20030208074-A1 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines SCHERING CORPORATION 2003-11-06 US claimed
WO-2003084942-A2 STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES SCHERING CORPORATION (US) 2003-10-16 WO claimed
EP-3302484-B1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-09-16 EP disclosed
EP-3302484-B1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME (US) 2020-09-16 EP disclosed
US-10160762-B2 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors MERCK SHARP & DOHME CORP. (US) 2018-12-25 US disclosed
US-10017508-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-07-10 US disclosed
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-17 US disclosed
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-17 US disclosed
EP-1546126-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES Central Glass Company, Limited (JP) 2005-06-29 EP disclosed
US-6872826-B2 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines SCHERING CORPORATION (US) 2005-03-29 US disclosed
EP-1490346-A2 STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES SCHERING CORPORATION (US) 2004-12-29 EP disclosed
JP-2004254554-A METHOD OF PRODUCING OPTICALLY ACTIVE 2-METHOXY-1-(4-TRIFLUOROMETHYL-PHENYL)ETHANOL MITSUBISHI CHEMICALS CORP 2004-09-16 JP disclosed
WO-2004014887-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-19 WO disclosed
US-20030208074-A1 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines SCHERING CORPORATION 2003-11-06 US disclosed
WO-2003084942-A2 STEREOSELECTIVE ALKYLATION OF CHIRAL 2-METHYL-4-PROTECTED PIPERAZINES SCHERING CORPORATION (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10160762-B2 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors PDE12, PDE2A, PDE4D ALDH1A1 705/4885MAPT 662/4885PTPN1 1350/4885
US-20180134712-A1 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D ALDH1A1 705/4885MAPT 662/4885PTPN1 1350/4885
US-20050171120-A1 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines AZI2, ALKBH5, DNMT1 ALDH1A1 578/4885MAPT 3482/4885PTPN1 4128/4885
US-20030208074-A1 Stereoselective alkylation of chiral 2-methyl-4-protected piperazines AZI2, DNMT1, ALKBH5 ALDH1A1 492/4885MAPT 3312/4885PTPN1 4028/4885
US-20100249411-A1 Stereoselective Alkylation of Chiral 2-Methly-4 Protected Piperazines ALKBH5, AZI2, PNMT ALDH1A1 449/4885MAPT 3509/4885PTPN1 3440/4885
US-10017508-B2 Nitrogenated heterocyclic compound PDE2A, PDE5A, PDE3A ALDH1A1 492/4885MAPT 487/4885PTPN1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.